We love to hear from our listeners. Send us a message.

On episode 125 of Cell & Gene: The Podcast, Host Erin Harris talks to Halloran Consulting Group's Monika Swietlicka to discuss how the FDA is increasing flexibility in cell and gene therapy development without lowering evidentiary standards, emphasizing a risk-based, holistic approach. They also explore what this means for developers, from platform strategies and global regulatory divergence to the growing role of patient advocacy and the need for early, integrated planning.

Subscribe to the podcast!
Apple  |  Spotify |  YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn